These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 21993737)

  • 41. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

  • 42. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Financial disclosure by clinical investigators; correction--FDA. Final rule; correction.
    Fed Regist; 1998 Jun; 63(124):35134. PubMed ID: 10180634
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The Medical Product Agency's work and economics--a comment].
    Ahlqvist Rastad J; Salmonson T
    Lakartidningen; 2003 Jan; 100(5):345. PubMed ID: 12607382
    [No Abstract]   [Full Text] [Related]  

  • 45. Doctors and drug companies--scrutinizing influential relationships.
    Campbell EG
    N Engl J Med; 2007 Nov; 357(18):1796-7. PubMed ID: 17978288
    [No Abstract]   [Full Text] [Related]  

  • 46. CIHR appointment.
    Roos NP; Baird P
    CMAJ; 2010 Jan; 182(1):65. PubMed ID: 20064969
    [No Abstract]   [Full Text] [Related]  

  • 47. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering?
    Purnhagen KP
    Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663
    [No Abstract]   [Full Text] [Related]  

  • 48. Trust, but verify.
    Nature; 2009 Sep; 461(7262):315. PubMed ID: 19759574
    [No Abstract]   [Full Text] [Related]  

  • 49. The drugs industry: a bad product well marketed.
    Abbasi K
    J R Soc Med; 2012 Jul; 105(7):275. PubMed ID: 22843642
    [No Abstract]   [Full Text] [Related]  

  • 50. Drug-review deadlines and safety problems.
    Carpenter D; Zucker EJ; Avorn J
    N Engl J Med; 2008 Mar; 358(13):1354-61. PubMed ID: 18367738
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The rise and fall of Natrecor for congestive heart failure: implications for drug policy.
    Kesselheim AS; Fischer MA; Avorn J
    Health Aff (Millwood); 2006; 25(4):1095-102. PubMed ID: 16835191
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Conflict of interest taints vaccine approval process, charges US report.
    McCarthy M
    Lancet; 2000 Sep; 356(9232):838. PubMed ID: 11022938
    [No Abstract]   [Full Text] [Related]  

  • 53. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT
    Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
    [No Abstract]   [Full Text] [Related]  

  • 54. The long arm of financial conflicts of interest: extensions into lined pockets, research and review, and the United States Senate.
    Rivkees SA
    J Pediatr Endocrinol Metab; 2008 Jul; 21(7):607-9. PubMed ID: 18780592
    [No Abstract]   [Full Text] [Related]  

  • 55. FDA publishes conflict of interest rules for clinical trials. Food and Drug Administration.
    James JS
    AIDS Treat News; 1998 Mar; (No 290):8. PubMed ID: 11365123
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transparency urged over research payments.
    Check E
    Nature; 2007 Aug; 448(7155):738. PubMed ID: 17700667
    [No Abstract]   [Full Text] [Related]  

  • 57. What ails the FDA?
    Okie S
    N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
    [No Abstract]   [Full Text] [Related]  

  • 58. [Jacques Servier (1922-2014) or the schizophrenic metaphor of Mediator].
    Nau JY
    Rev Med Suisse; 2014 Apr; 10(428):990-1. PubMed ID: 24834626
    [No Abstract]   [Full Text] [Related]  

  • 59. Conflict of interest rules seen by some as too stringent.
    Willyard C
    Nat Med; 2009 Jul; 15(7):709. PubMed ID: 19584838
    [No Abstract]   [Full Text] [Related]  

  • 60. France to prosecute its drug regulator and Servier in scandal over diabetes drug.
    Dyer O
    BMJ; 2017 Sep; 358():j4231. PubMed ID: 28893847
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.